CRDL - Cardiol Therapeutics Inc Class A

CRDL - Cardiol Therapeutics Inc Class A

https://www.cardiolrx.com

Recent News

Powered by Alpha Vantage

This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Aspen Insurance Hldgs ( NYSE:AHL ) , Cardiol Therapeutics ( NASDAQ:CRDL )

Benzinga • 3 months, 1 week ago • score: 0.14

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Cardiol Therapeutics Stock: Is Cannabis Potential Priced In?

Zacks Commentary • 4 months, 3 weeks ago • score: 0.21

Cardiol Therapeutics shows promise with its CBD-based heart therapy, but a lack of approved drugs and a narrow pipeline raise red flags for cautious investors.

Is Cogent Biosciences ( COGT ) Outperforming Other Medical Stocks This Year?

Zacks Commentary • 7 months ago • score: 0.16

Here is how Cogent Biosciences, Inc. (COGT) and Cardiol Therapeutics Inc. (CRDL) have performed compared to their sector so far this year.

Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index - Cardiol Therapeutics ( NASDAQ:CRDL )

Benzinga • 10 months ago • score: 0.40

NEW YORK, Nov. 13, 2024 ( GLOBE NEWSWIRE ) -- PRISM MarketView, a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc. CRDLCRDL has been added to the PRISM Emerging Biotech Index, which spotlights companies leading innovation and creating market ...

Are Medical Stocks Lagging Cardiol Therapeutics ( CRDL ) This Year?

Zacks Commentary • 10 months, 3 weeks ago • score: 0.43

Here is how Cardiol Therapeutics Inc. (CRDL) and Catalent (CTLT) have performed compared to their sector so far this year.

Why Cardiol Therapeutics ( CRDL ) Stock Is Down 20% Today - Cardiol Therapeutics ( NASDAQ:CRDL )

Benzinga • 11 months ago • score: 0.21

Cardiol Therapeutics Inc CRDL shares are trading lower by 18.4% to $1.60 Wednesday morning after the company announced a $13.5 million public offering of 8,437,500 common shares priced at $1.60 per unit.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Cardiol Therapeutics Inc., a clinical-phase biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment of cardiovascular diseases (CVD). The company is headquartered in Oakville, Canada.

52W High

$2.63

52W Low

$0.77

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.61

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.30

EV/Revenue (<3 favorable)

178.81

P/S (TTM) (<3 favorable)

1069.35

P/B (<3 favorable)

10.66

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

4.29%

Institutions (25–75% balanced)

8.53%

Shares Outstanding

83,729,000

Float

80,679,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

78,760

EPS (TTM)

-0.35

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-2.76%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—